Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)

Inclusion Criteria:

• Was randomized, received at least 1 dose of study intervention (vericiguat orplacebo), and completed the Week 52 visit and safety follow-up period for the VALORbase study.

• A participant assigned female sex at birth is not pregnant or breastfeeding, and isnot a participant/participants of childbearing potential (POCBP) or is a POCBP whoUses a contraceptive method that is highly effective, has a negative highlysensitive pregnancy test, abstains from breastfeeding during the study interventionperiod and for at least 30 days after study intervention., and whose medicalhistory, menstrual history, and recent sexual activity has been reviewed by theinvestigator to decrease the risk for inclusion of a POCBP with an early undetectedpregnancy.

• Is able to receive medication via the oral or gastric route .

Exclusion Criteria:

• Is hypotensive for age at Visit 1

• Has a known allergy or sensitivity to vericiguat, any of its constituents, or anyother soluble guanylate cyclase (sGC )stimulator.

• Has undergone heart transplantation or has an implanted ventricular assist device.

• Has severe chronic kidney disease

• Has hepatic disorder

• Has concurrent or anticipated concomitant use of phosphodiesterase type 5 inhibitorsduring the study.

• Has concurrent or anticipated use of an sGC stimulator.

• Is both ≥18 years of age and vericiguat is commercially available to the participant